I am pleased to announce the release of the 2016 Treatment of Drug-Susceptible Tuberculosis Guidelines. The American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) sponsored the development of the guidelines, and they have been endorsed by the European Respiratory Society and the U.S. National Tuberculosis Controllers Association. The guidelines update the previous tuberculosis (TB) treatment guidelines published by ATS/CDC/IDSA in 2003.
The newly released guidelines provide recommendations on the clinical and public health management of tuberculosis (TB) in children and adults in well-resourced settings. The guidelines provide evidence-based recommendations that were developed with the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology. GRADE involves structured literature review, systematic reviews and meta-analyses of combined data, and expert discussion to assess the certainty in the evidence and determine the strength of each recommendation. Among the nine recommendations for the treatment of drug-susceptible TB, the guidelines provide recommendations on the management of patients who are co-infected with TB disease and HIV. They also include sections on TB disease in special situations, such as extrapulmonary TB, culture-negative pulmonary TB, and TB during pregnancy and breastfeeding, among others.
Help us spread the word about the new TB treatment guidelines. We have provided a matte article that can be used to share this information with your partners and stakeholders. Please feel free to revise and personalize for your own media outlets. For more information on the management of TB disease and practice recommendations, please see the full version of the guidelines in Clinical Infectious Diseases.
Philip LoBue, MD, FACP, FCCP
Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention